Condition
Immune Evasion, Tumor
Total Trials
4
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 2 (1)
Trial Status
Unknown2
Recruiting1
Terminated1
Clinical Trials (4)
Showing 4 of 4 trials
NCT03960021Not ApplicableTerminatedPrimary
Immune Mechanisms After Radiofrequency Ablation of Pulmonary Metastases From Colorectal Cancer Origin
NCT07034339RecruitingPrimary
Construction and Clinical Application of the Immune Map of Pancreatic Cancer Evolution
NCT05241132Phase 2Unknown
Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary
NCT03964922Not ApplicableUnknown
Immunoevasive Tactics Employed by Myeloid Malignancy After Allogeneic Stem Cell Transplantation
Showing all 4 trials